Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6010 ± SYH2051 versus investigator’s choice of chemotherapy in EGFR-expressing advanced solid tumors
CTR20244836Phase 2Active
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Dec 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CPO301 in Nonhematologic neoplasms, breast cancer, sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Started Dec 2024; status: active.
02
Drugs
CPO301
03
Conditions
Nonhematologic neoplasmsbreast cancer
Beyond the preview
Go deeper on CTR20244836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244836.